PSNL News and Press, Personalis Inc. From 05/29/20

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in abstracts to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, which will be held May 29-31, 2020. One abstr...

Image source: The Motley Fool. Personalis, Inc.   (NASDAQ: PSNL) Q1 2020 Earnings Call May 07, 2020 , 5:00 p.m. ET Operator Continue reading

Personalis, Inc. (PSNL) Q1 2020 Earnings Conference Call May 07, 2020 5:00 PM ET Company Participants Caroline Corner – Westwicke ICR John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants ...

Personalis (NASDAQ: PSNL ): Q1 GAAP EPS of -$0.29 misses by $0.01 . More news on: Personalis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the first quarter ended March 31, 2020. First Quarter Highlights Reported record revenues of $19.2 million in the first quarter of 2020 versus $14.1 million in the first...

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the appointment Stephen Moore as General Counsel. “We are very pleased to welcome Stephen to the Personalis team. He has an impressive track record with more than 20 years of in-house legal e...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in three upcoming virtual investor conferences. Present at the Bank of America Securities 2020 Health Care Conference scheduled to be held virtually on Thu...

Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded re-accreditation to the Personalis Clinical Laboratory , Menlo Park, California based on results of a recent on-site...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its first quarter 2020 financial results after the market closes on Thursday, May 7, 2020. In conjunction with the release, the Company will host a conference call and webcast that day a...

HAMBURG, Germany and MENLO PARK, Calif. , April 21, 2020 /PRNewswire/ -- Indivumed GmbH ("Indivumed") and Personalis, Inc. (Nasdaq: PSNL) today announced that the two companies have entered into a collaboration in the field of personalized oncology. The partnership seeks to enable ...